Literature DB >> 10349868

Effects of erythropoietin on neuronal activity.

K Koshimura1, Y Murakami, M Sohmiya, J Tanaka, Y Kato.   

Abstract

Recently, erythropoietin (EPO) receptors and synthesis of EPO have been identified in the brain. To clarify the effects of EPO on neuronal cells, we investigated the effects of EPO on Ca2+ uptake, intracellular Ca2+ concentration, membrane potential, cell survival, release and biosynthesis of dopamine, and nitric oxide (NO) production in differentiated PC12 cells, which possess EPO receptors. EPO (10(-12)-10(-10) M) increased 45Ca2+ uptake and intracellular Ca2+ concentration in PC12 cells in a dose-related manner; these increases were inhibited by nicardipine (1 microM) or anti-EPO antibody (1:100 dilution). EPO induced membrane depolarization in PC12 cells. After a 5-day culture without serum and nerve growth factor (NGF), viable cell number decreased to 50% of that of the control cells cultured with serum and NGF. EPO (10(-13)-10(-10) M) increased the number of viable cells cultured without serum and NGF; this increase was blunted by nicardipine or anti-EPO antibody. Incubation with EPO (10(-13)-10(-10) M) stimulated mitogen-activated protein kinase activity in PC12 cells. EPO (10(-13)-10(-10) M) increased dopamine release from PC12 cells and tyrosine hydroxylase activity; these increases were sensitive to nicardipine or anti-EPO antibody. Following a 4-h incubation with EPO (10(-14)-10(-10) M), NO production was increased, which was blunted by nicardipine and anti-EPO antibody. In contrast, maximal NO synthase activity was not changed by EPO. These results suggest that EPO stimulates neuronal function and viability via activation of Ca2+ channels.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10349868     DOI: 10.1046/j.1471-4159.1999.0722565.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  28 in total

Review 1.  Angiotensin AT2 receptor ligands: do they have potential as future treatments for neurological disease?

Authors:  Philip Rosenstiel; Stefan Gallinat; Alexander Arlt; Thomas Unger; Jobst Sievers; Ralph Lucius
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

2.  Erythropoietin: still on the neuroprotection road.

Authors:  Nelvys Subirós; Diana García Del Barco; Rosa M Coro-Antich
Journal:  Ther Adv Neurol Disord       Date:  2012-05       Impact factor: 6.570

3.  Erythropoietin requires NF-kappaB and its nuclear translocation to prevent early and late apoptotic neuronal injury during beta-amyloid toxicity.

Authors:  Zhao Zhong Chong; Faqi Li; Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2005-12       Impact factor: 1.990

Review 4.  The neurobiology of erythropoietin.

Authors:  Arthur J Sytkowski
Journal:  Cell Mol Neurobiol       Date:  2011-05-03       Impact factor: 5.046

5.  Erythropoietin neuroprotection with traumatic brain injury.

Authors:  Lucido L Ponce; Jovany Cruz Navarro; Osama Ahmed; Claudia S Robertson
Journal:  Pathophysiology       Date:  2012-03-14

6.  Erythropoietin Treatment Exacerbates Moderate Injury after Hypoxia-Ischemia in Neonatal Superoxide Dismutase Transgenic Mice.

Authors:  R Ann Sheldon; Christine Windsor; Byong Sop Lee; Olatz Arteaga Cabeza; Donna M Ferriero
Journal:  Dev Neurosci       Date:  2017-04-27       Impact factor: 2.984

7.  Erythropoietin fosters both intrinsic and extrinsic neuronal protection through modulation of microglia, Akt1, Bad, and caspase-mediated pathways.

Authors:  Zhao Zhong Chong; Jing-Qiong Kang; Kenneth Maiese
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

8.  The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin.

Authors:  Anargyros Xenocostas; Wing K Cheung; Francis Farrell; Cindy Zakszewski; Marian Kelley; Andrzej Lutynski; Michael Crump; Jeffrey H Lipton; Thomas L Kiss; Catherine Y Lau; Hans A Messner
Journal:  Eur J Clin Pharmacol       Date:  2005-03-18       Impact factor: 2.953

9.  Erythropoietin: a multimodal neuroprotective agent.

Authors:  Nadiya Byts; Anna-Leena Sirén
Journal:  Exp Transl Stroke Med       Date:  2009-10-21

10.  Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo.

Authors:  Serhat Erbayraktar; Giovanni Grasso; Alessandra Sfacteria; Qiao-wen Xie; Thomas Coleman; Mads Kreilgaard; Lars Torup; Thomas Sager; Zubeyde Erbayraktar; Necati Gokmen; Osman Yilmaz; Pietro Ghezzi; Pia Villa; Maddalena Fratelli; Simona Casagrande; Marcel Leist; Lone Helboe; Jens Gerwein; Søren Christensen; Marie Aavang Geist; Lars Østergaard Pedersen; Carla Cerami-Hand; Jean-Paul Wuerth; Anthony Cerami; Michael Brines
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.